Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

The next-generation human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278) was administered in rats and dogs as single intramuscular (IM) or subcutaneous (SC) injections, formulated as a 200-nm nanosuspension. The plasma pharmacokinetics, injec...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: van ′t Klooster, Gerben, Hoeben, Eva, Borghys, Herman, Looszova, Adriana, Bouche, Marie-Paule, van Velsen, Frans, Baert, Lieven
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology (ASM) 2010
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2863620/
https://ncbi.nlm.nih.gov/pubmed/20160045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01529-09
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares